APLM

Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate.

Wall Street analysts forecast APLM stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLM is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Apollomics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Apollomics Inc. EPS for the last quarter amounts to -0.00 USD, decreased -100.00 % YoY.

Apollomics Inc (APLM) has 13 emplpoyees as of January 10 2026.

Today APLM has the market capitalization of 47.15M USD.